Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown

AAV Serotype Comparison for LRRK2 Knockdown in Parkinson's Disease Gene Therapy

Experiment Category: Gene Therapy Approaches Created: 2026-03-21 Slot: 5

Hypothesis

Systematic comparison of AAV serotypes (AAV2/9, AAV-PHP.B, AAV-KO) will identify optimal vectors for delivering [LRRK2](/entities/lrrk2)-targeted shRNA to the substantia nigra and striatum, with AAV-PHP.B demonstrating superior transduction efficiency and reduced immunogenicity compared to traditional serotypes.

Specific Aims

Background

LRRK2 (Leucine-Rich Repeat Kinase 2) mutations are the most common cause of autosomal-dominant Parkinson's disease, accounting for 5-10% of familial PD cases. Gene therapy approaches using AAV vectors to deliver LRRK2-targeted shRNA or CRISPR components hold promise, but optimal delivery vectors for CNS applications remain unclear.

Detailed Protocol

Vector Construction

• Design 3 LRRK2-targeted shRNA sequences (targeting exon 2, exon 31, exon 41)
• Clone into AAV backbone with H1 or U6 promoter
• Include GFP reporter for transduction verification
• Produce high-titer vectors for each serotype

AAV Serotype Comparison for LRRK2 Knockdown in Parkinson's Disease Gene Therapy

Experiment Category: Gene Therapy Approaches Created: 2026-03-21 Slot: 5

Hypothesis

Systematic comparison of AAV serotypes (AAV2/9, AAV-PHP.B, AAV-KO) will identify optimal vectors for delivering [LRRK2](/entities/lrrk2)-targeted shRNA to the substantia nigra and striatum, with AAV-PHP.B demonstrating superior transduction efficiency and reduced immunogenicity compared to traditional serotypes.

Specific Aims

Background

LRRK2 (Leucine-Rich Repeat Kinase 2) mutations are the most common cause of autosomal-dominant Parkinson's disease, accounting for 5-10% of familial PD cases. Gene therapy approaches using AAV vectors to deliver LRRK2-targeted shRNA or CRISPR components hold promise, but optimal delivery vectors for CNS applications remain unclear.

Detailed Protocol

Vector Construction

• Design 3 LRRK2-targeted shRNA sequences (targeting exon 2, exon 31, exon 41)
• Clone into AAV backbone with H1 or U6 promoter
• Include GFP reporter for transduction verification
• Produce high-titer vectors for each serotype

Animal Groups

• C57BL/6 mice (n=10/serotype/group)
• Adult rhesus macaques (n=3/serotype)
• Untreated controls (n=5 mice, 1 NHP)
• Wild-type AAV injected (n=5 mice)

Surgical Delivery

• Stereotactic injection into substantia nigra pars compacta (SNc)
• Coordinates: AP -3.0, ML ±1.3, DV -4.5 (mouse)
• Bilateral injection, 2μL per hemisphere (mouse)
• NHP: multiple injection sites targeting SNc and striatum

Outcome Measures

• Primary: LRRK2 mRNA expression (qPCR) in SNc at 4, 12, 24 weeks
• Primary: GFP+ neuron count (immunohistochemistry)
• Secondary: Tyrosine hydroxylase (TH) + neuron survival
• Secondary: Behavioral testing (cylinder, forelimb akinesia, rotarod)
• Safety: Cytokine panels, immune cell infiltration, liver function

Reagents and Costs

| Item | Unit Cost | Quantity | Total |
|------|-----------|----------|-------|
| AAV vector production (5 serotypes) | $8,000/serotype | 5 | $40,000 |
| shRNA design & cloning | $5,000 | 1 | $5,000 |
| Mouse purchase (C57BL/6) | $25 | 75 | $1,875 |
| Mouse housing (6 months) | $35/month | 75 | $15,750 |
| NHP (rhesus macaque) | $12,000 | 9 | $108,000 |
| NHP housing (12 months) | $800/month | 9 | $86,400 |
| Stereotactic surgery | $500 | 20 surgeries | $10,000 |
| qPCR reagents | $3,000 | 3 runs | $9,000 |
| IHC antibodies & reagents | $8,000 | 1 | $8,000 |
| Behavioral testing equipment | $15,000 | 1 | $15,000 |
| Cytokine panel assays | $500 | 40 | $20,000 |
| Histology services | $12,000 | 1 | $12,000 |
| Data analysis software | $5,000 | 1 | $5,000 |
| Personnel (2 FTEs, 18 months) | $6,000/month | 36 months | $432,000 |
| TOTAL | | | $767,025 |

Suggested Labs/Investigators (Geographic Diversity)

| Investigator | Institution | Country | Expertise |
|--------------|-------------|---------|-----------|
| Dr. Michael Kaplitt | Weill Cornell Medicine | USA | AAV gene therapy, CNS |
| Dr. Viviana Gradinaru | Caltech | USA | AAV-PHP.B, vector engineering |
| Dr. Krystof Bankiewicz | UCSF | USA | NHP gene therapy, Parkinson's |
| Dr. Mark Bezard | Université de Bordeaux | France | AAV, NHP models |
| Dr. Jerald K. C. Chiang | Academia Sinica | Taiwan | AAV serotype comparison |
| Dr. Takashi Shimada | Juntendo University | Japan | Gene therapy, AAV |
| Dr. Nicola J. Brill | Charité Berlin | Germany | NHP neuroscience |
| Dr. M. R. K. Sahin | Istanbul University | Turkey | Neurodegeneration, gene therapy |

Timeline

| Phase | Duration | Activities |
|-------|----------|------------|
| Phase 1: Design & Production | Months 1-4 | shRNA design, vector production, pilot testing |
| Phase 2: Mouse Studies | Months 5-10 | Serotype comparison in mice, dose optimization |
| Phase 3: NHP Studies | Months 8-18 | Validation in non-human primates |
| Phase 4: Analysis | Months 16-20 | Comprehensive analysis, manuscript preparation |

Total Duration: 20 months

Scoring (10 Dimensions)

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Scientific Value | 10 | Directly addresses LRRK2 mechanism; high relevance to PD |
| Feasibility | 7 | Requires specialized AAV production; NHP access challenging |
| Novelty | 9 | First comprehensive serotype comparison for LRRK2 |
| Disease Impact | 10 | Could enable clinical LRRK2 gene therapy |
| Reach | 8 | Findings applicable to other CNS gene therapy |
| Cost Efficiency | 6 | High cost but significant long-term impact |
| Time Efficiency | 7 | 20 months reasonable for comprehensive study |
| Evidence Base | 8 | Strong preclinical rationale from existing LRRK2 work |
| Addresses Uncertainty | 10 | Critical gap: optimal AAV serotype unknown |
| Translation Potential | 10 | Directly enables IND-enabling studies |

Raw Score: 85/100 Weighted Score: 126/140

Cross-Links to NeuroWiki Pages

• [LRRK2](/genes/lrrk2) - Target gene
• [LRRK2 Protein](/proteins/lrrk2-protein) - Protein product
• [Parkinson's Disease](/diseases/parkinsons-disease) - Target disease
• [AAV Vectors for Neurodegenerative Gene Therapy](/therapeutics/aav-vectors-neurodegenerative-gene-therapy) - Vector platform
• [Substantia Nigra](/cell-types/dopaminergic-neurons) - Target brain region
• [Gene Therapy for Parkinson's](/therapeutics/gene-therapy-parkinsons) - Related treatment
• [G2019S LRRK2 Mutation](/diseases/lrrk2-g2019s-parkinsonism) - Common mutation

Evidence Gap Addressed

This experiment fills a critical gap in the current portfolio:

• Gap: Gene therapy approaches have not been systematically explored in our experiment database
• Impact: LRRK2 is a high-value target but delivery optimization is a major barrier to clinical translation
• Uniqueness: No head-to-head comparison of AAV-PHP.B vs traditional serotypes for LRRK2 targeting exists

See Also

• [Mechanisms](/mechanisms)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [ClinicalTrials.gov](https://clinicaltrials.gov/)

References